Use of sofosbuvir in chronic kidney disease: Is it necessary?
作者信息
Lim Tae Seop, Ahn Sang Hoon
机构信息
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2017 Dec;23(4):308-310. doi: 10.3350/cmh.2017.0109. Epub 2017 Sep 26.
Abstract
摘要
相似文献
1
Use of sofosbuvir in chronic kidney disease: Is it necessary?索磷布韦在慢性肾脏病中的应用：有必要吗？
Clin Mol Hepatol. 2017 Dec;23(4):308-310. doi: 10.3350/cmh.2017.0109. Epub 2017 Sep 26.
2
Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.来迪派韦索磷布韦治疗伴中度肾功能损害的 1b 型慢性丙型肝炎病毒感染患者的疗效和安全性。
Hepatol Int. 2018 Mar;12(2):133-142. doi: 10.1007/s12072-018-9859-9. Epub 2018 Mar 29.
3
Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.低剂量索磷布韦治疗严重肾功能损害或终末期肾病慢性丙型肝炎患者安全有效。
Dig Dis Sci. 2018 May;63(5):1334-1340. doi: 10.1007/s10620-018-4979-6. Epub 2018 Feb 26.
4
New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.慢性肾脏病、透析和移植患者丙型肝炎的新疗法。
Kidney Int. 2016 May;89(5):988-994. doi: 10.1016/j.kint.2016.01.011. Epub 2016 Mar 11.
5
Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.索磷布韦与利巴韦林联合治疗慢性丙型肝炎感染
Expert Rev Gastroenterol Hepatol. 2016;10(1):21-36. doi: 10.1586/17474124.2016.1119042. Epub 2015 Dec 11.
6
Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min.索磷布韦和西米普明用于丙型肝炎基因1型患者——接受血液透析或肾小球滤过率<30 ml/分钟的终末期肾病患者。
Liver Int. 2016 Jun;36(6):798-801. doi: 10.1111/liv.13025. Epub 2015 Dec 15.
7
Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.索磷布韦治疗慢性丙型肝炎：新的方法，新的疗效。
Clin Infect Dis. 2014 Aug 1;59(3):411-5. doi: 10.1093/cid/ciu265. Epub 2014 Apr 18.
8
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.在接受血液透析的慢性丙型肝炎患者中，每日给予全剂量索非布韦为基础的方案的药代动力学、安全性和疗效。
J Hepatol. 2016 Jul;65(1):40-47. doi: 10.1016/j.jhep.2016.02.044. Epub 2016 Mar 4.
9
Sofosbuvir Monotherapy for Asymptomatic and Noncirrhotic Hepatitis C Infection in a Renal Retransplantation Recipient: A Case Report.索磷布韦单药治疗肾再移植受者无症状非肝硬化丙型肝炎感染：一例报告
Transplant Proc. 2016 Nov;48(9):3120-3122. doi: 10.1016/j.transproceed.2016.05.003.
10
Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian "real-life" study.基于索磷布韦的慢性丙型肝炎治疗一年后的肾脏安全性：一项巴西的“真实世界”研究。
J Clin Pharm Ther. 2018 Oct;43(5):707-713. doi: 10.1111/jcpt.12697. Epub 2018 May 7.
引用本文的文献
1
Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment.索磷布韦与肾功能损害患者估算肾小球滤过率下降或终末期肾病风险
Aliment Pharmacol Ther. 2022 May;55(9):1169-1178. doi: 10.1111/apt.16830. Epub 2022 Mar 2.
2
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.血清中性粒细胞明胶酶相关载脂蛋白（NGAL）在接受索非布韦治疗的埃及 HCV 阳性患者中的变化。
Can J Gastroenterol Hepatol. 2020 Jan 27;2020:1632959. doi: 10.1155/2020/1632959. eCollection 2020.
本文引用的文献
1
Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.索磷布韦为基础的方案治疗慢性丙型肝炎基因型 1 患者中肾功能中度受损的疗效和安全性。
Clin Mol Hepatol. 2017 Dec;23(4):316-322. doi: 10.3350/cmh.2016.0087. Epub 2017 Aug 22.
2
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories.慢性丙型肝炎与慢性肾脏病：进展、局限与未知领域
J Viral Hepat. 2017 Jun;24(6):442-453. doi: 10.1111/jvh.12681. Epub 2017 Feb 22.
3
Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.肾功能损害患者丙型肝炎病毒感染的新疗法。
J Clin Transl Hepatol. 2016 Dec 28;4(4):320-327. doi: 10.14218/JCTH.2016.00032. Epub 2016 Dec 26.
4
EASL Recommendations on Treatment of Hepatitis C 2016.2016年欧洲肝脏研究学会丙型肝炎治疗指南
J Hepatol. 2017 Jan;66(1):153-194. doi: 10.1016/j.jhep.2016.09.001. Epub 2016 Sep 22.
5
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.含索磷布韦方案在肾功能受损的丙型肝炎感染患者中的安全性和有效性。
Liver Int. 2016 Jun;36(6):807-16. doi: 10.1111/liv.13102. Epub 2016 Mar 24.
6
Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.半剂量索磷布韦联合西米普瑞韦治疗终末期肾病患者丙型肝炎的安全性、有效性和耐受性
J Hepatol. 2015 Sep;63(3):763-5. doi: 10.1016/j.jhep.2015.06.004. Epub 2015 Jun 18.
7
A nationwide seroepidemiology of hepatitis C virus infection in South Korea.韩国全国丙型肝炎病毒感染的血清流行病学研究。
Liver Int. 2013 Apr;33(4):586-94. doi: 10.1111/liv.12108. Epub 2013 Jan 29.
8
Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.慢性丙型肝炎病毒感染血液透析患者的干扰素治疗：文献系统评价及治疗疗效与危害的荟萃分析
Am J Kidney Dis. 2008 Feb;51(2):263-77. doi: 10.1053/j.ajkd.2007.11.003.
9
Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials.透析患者慢性丙型肝炎的干扰素单药治疗：临床试验的荟萃分析
J Viral Hepat. 2008 Feb;15(2):79-88. doi: 10.1111/j.1365-2893.2007.00907.x.
10
The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies.丙型肝炎病毒感染对透析患者生存的影响：观察性研究的荟萃分析
J Viral Hepat. 2007 Oct;14(10):697-703. doi: 10.1111/j.1365-2893.2007.00868.x.
Zotero 插件